Bibliography
- MANN KG, JENNY RJ, KRISHNASWAMY S: Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann. Rev Biochem.(1988) 57:915–956.
- WEITZ JI. Low-molecular-weight heparins [published erratum appears in N. Engl. J. Med. (1997) 337 (21):15671. N Engl. J Med.(1997) 337:688–698.
- ••Recent review of current practices inanticoagulant therapy.
- HIRSH J, FOSTER V: Guide to anticoagulant therapy, Part 2:oral anticoagulants. Circulation(1994) 89:1469–1480.
- GABRIEL B, STUBBS M, BERGNER A et al.:Design of benzamidine-type Inhibitors of Factor Xa. j Med. Chem.(1998) 41:4240–4250.
- ZHU B-Y, SCARBOROUGH RM: Recent advances in inhibitors of Factor Xa in the prothrombinase complex. Curr. Opiri. Cardiovasc. Pulm. Renal Invest. Drugs(1999) 1:63–88.
- HARA T, YOKOYAMA A, ISHIHARA H, YOKOYAMA Y, NAGAHARA T, IWAMOTO M: DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for Factor Xa. Thromb. Haemost. (1994) 71:314–319.
- BRANDSTETTER H, KOHNE A, BODE W et al.:X-ray structure of active site-inhibited clotting Factor Xa. Implications for drug design and substrate recognition. _J. Biol. Chem.(1996) 271:29988–29992.
- ••Description of substrate binding to factor Xa.
- STUBBS MT, HUBER R, BODE W: Crystal structures of Factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of Factor Xa and selectivity against thrombin. FEBS Lett.(1995) 375:103–107.
- NAGAHARA T, YOKOYAMA Y, INAMURA K et al:Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation Factor Xa inhibitors. j Med. Chem.(1994) 37:1200–1207.
- KAMATA K, H HK, HONMA T, IWAMA T, KIM SH: Structural basis for chemical inhibition of human blood coagulation Factor Xa. Proc. Natl. Acad. Sci. USA(1998) 95:6630–6635.
- QUAN ML, ELLIS CD, LIAUW AY et al:Design and synthesis of isoxazoline derivatives as Factor Xa inhibitors. 2. _J. Med. Chem.(1999) 42:2760–2773.
- MAIGNAN S, GUILLOTEAU JP, POUZIEUX S etal.Crystal structures of human Factor Xa complexed with potent inhibitors. j Med. Chem.(2000) 43:3226–3232.
- •Design of non-basic inbibitors of factor Xa.
- QUAN ML, ELLIS CD, LIAUW AY et al:Design and synthesis of isoxazoline derivatives as Factor Xa inhibitors. 2. _J. Med. Chem.(1999) 42:2760–2773.
- FEVIG JM, PINTO DJ, HAN Q et alSynthesis and SAR of benzamidine Factor Xa inhibitors containing a vicinally-substituted heterocyclic core. Bioorg. Med. Chem. Lett.(2001) 11:641–645.
- LAM PYS, LI R, CLARK CG et alStructure-based design and discovery of orally bioavailable potent nonbenzamidine factor Xa inhibitors. ACS meeting.San Francisco, USA (2000) March. MEDI160.
- PINTO DJ, ORWAT MJ, WANG S et al:Discovery of 1- [3- (aminomethyflphenyli-N-3-fluoro-2 (kmethylsulfony1)- [1, 1'-biphenyl] 4 yl] 3 (trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation Factor Xa. J. Med. Chem.(2001) 44:566–578.
- •Pharmacokinetic profile of a factor Xa inhibitors with non-basic resiudes in Pl.
- ROGERS KL, CHI L, RAPUNDALO ST, KRAMER JB, GALLAGHER KP: Effects of a Factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis. Basic Res. Cardiol.(1999) 94:15–22.
- WEI A, ALEXANDER RS, DUKE J, ROSS H, ROSENFELD SA, CHANG CH: Unexpected binding mode of tick anticoagulant peptide complexed to bovine Factor Xa. j Mal Biol.(1998) 283:147–154.
- •Occupation of the P1 pocket of Factor Xa by a tyrosine residue.
- BECKER MR, EWING WR, DAVIS RS et al.:Synthesis, SAR and in vivoactivity of novel thienopyridine sulfonamide pyrrolidinones as Factor Xa inhibitors. Bioorg. Med. Chem. Lett.(1999) 9:2753–2758.
- HEW, HANNEY B, MYERS MR et al: Nonbenzamidine compounds as selective Factor Xa inhibitors. Bioorg. Med. Chem. Lett.(2000) 10:1737–1739.
- HERRON DK, GOODSON T, JR., WILEY MR et at.:1,2- Dibenzamidobenzene inhibitors of human Factor Xa. j Med. Chem.(2000) 43:859–872.
- MASTERS JJ, FRANCISKOVICH JB, TINSLEY JM et al.:Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human Factor Xa with potent anticoagulant and antithrombotic activity. Med. Chem.(2000) 43:2087–2092.
- YEE YK, TEBBE AL, LINEBARGER JH et al.:N(2)-Aroylanthranilamide inhibitors of human Factor Xa. j Med. Chem.(2000) 43:873–882.
- WITLOW M, ARNAIZ DO, BUCKMAN BO et al.:Crystallographic analysis of potent and selective Factor Xa inhibitors complexed to bovine trypsin. Acta Crystallographica(1999) D55:1395–1404.
- ADLER M, DAVEY DD, PHILLIPS GB etal.:Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with Factor Xa. Biochemistry(2000) 39:12534–42.
- •Binding of the active site serine of factor Xa to a non-transition state inhibitor.
- PHILLIPS GB, BUCKMAN BO, DAVEY DD etal.:Discovery of N- [2- [5-[Amino(imino)methyl[-2-hydroxyphenoxy]-3, 5-difluoro-6- [3- (4,5-dihydro-1-methy1-1H-imidazol-2- yflphenoxylpyridin-4-y11-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme Factor Xa. j Med. Chem(1998) 41:3557–62.
- REHWINKEL JBM, LUCAS H, GALEN PJMV et al:1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Bioorg. Med. Chem. Lett.(1999) 9:685–690.
- AL-OBEIDI F, OSTREM JA: Factor Xa inhibitors. Expert Opiri. Ther. Patents(1999) 9:931–953.